Guggenheim raised the firm’s price target on Pfizer (PFE) to $36 from $35 and keeps a Buy rating on the shares. Topline data for Pfizer’s MEVPRO-1 Phase 3 trial of mevrometostat in second-line and later mCRPC is expected to read out in the second half of 2026, notes the analyst, who sees $2 per share potential upside on success versus about $1 downside on failure.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
- Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
- Pfizer (PFE) Balances Trial Setback With Quiet Pipeline Push
- Pfizer recommends shareholders reject mini-tender offer by Tutanota
- Pfizer’s talzenna plus xtandi shows improved survival in prostate cancer